MyMedR

Displaying all 6 publications

Abstract:

Sort:

Fulltext Kesan senaman aerobik terhadap penanda stres terpilih di kalangan pelajar semasa musim peperiksaan akademik

Farah Fauzi, Arimi Fitri Mat Ludin, Mahadir Ahmad, Kamarul Zaman Maidin

Jurnal Sains Kesihatan Malaysia, 2006;4(2):27-37.
MyJurnal

Aktiviti fizikal yang kerap seperti senaman mempunyai implikasi yang baik terhadap kehidupan seharian kita terutamanya dalam aspek kesihatan dan pengurusan stres. Kajian ini adalah bertujuan untuk mengkaji kesan program senaman aerobik dengan protokol yang ditetapkan ke atas aras penanda tekanan terpilih di kalangan pelajar universiti semasa musim peperiksaan akademik. Lapan belas (n=18) mahasiswa tidak terlatih, dipadankan dengan umur dan BMI, telah dibahagikan kepada 2 kumpulan iaitu kumpulan intervensi (n=10) dan kawalan (n=8). Kumpulan intervensi menjalani senaman jenis aerobik berintensiti sederhana (60-75% daripada kadar denyut jantung maksimum), 3 kali seminggu selama 40-50 minit untuk setiap sesi selama 6 minggu. Darah vena diambil pada sebelum program senaman bermula (M1) dan selepas program senaman berakhir (M2) iaitu dalam minggu pertama musim peperiksaan. Kecergasan kardiorespiratori dan status stres psikologi diukur sebelum kedua-dua sesi pengambilan darah. Analisis biokima dijalankan untuk melihat aras malondialdehid (MDA) plasma dan kortisol serum. Hasil kajian menunjukkan bahawa program senaman selama 6 minggu ini telah merangsang penurunan aras MDA yang signifikan (F=19.58, p=0.002) semasa minggu peperiksaan berbanding aras sebelum program senaman bermula. Kumpulan intervensi juga menunjukkan aras MDA yang lebih rendah (t=-0.42, p=0.001) berbanding kumpulan kawalan semasa menduduki minggu peperiksaan. Walaubagaimanapun, tiada perbezaan yang signifikan pada aras kortisol dalam kedua-dua kumpulan walaupun terdapat penurunan yang sedikit pada kumpulan intervensi semasa minggu peperiksaan. Kajian ini mencadangkan bahawa program senaman yang dijalankan mampu dijadikan sebagai strategi yang berkesan untuk membantu pelajar menghadapi stres terutamanya sewaktu sesi akademik yang memberatkan.

Matched MeSH terms: Vidarabine
Kesan kadar nitrogen terhadap populasi lalat putih (bemisia tabaci) pada tanaman cili (capsicum annum L.)

Zurina M, Idris A, Mohamad Roff M

Sains Malaysiana, 2010;39.

Bemisia tabaci (Gennadius) merupakan spesies lalat putih utama dan berbahaya kepada pertanian. Kajian telah dijalankan di Stesen MARDI Jalan Kebun, Klang, Selangor dari 9 September 2006 hingga 11 November 2007. Objektif kajian ini adalah untuk menilai kesan populasi lalat putih terhadap tanaman cili yang diberi kadar nitrogen yang berbeza (0, 33, 43, 53 g/pokok). Keputusan kajian menunjukkan pokok cili yang dibaja dengan kadar nitrogen yang tinggi menyebabkan peningkatan yang bererti (P<0.05) kepada populasi B. tabaci peringkat belum matang berbanding pada pokok cili yang dibajakan nitrogen pada kadar rendah. Min bilangan B. tabaci pada peringkat belum matang per aras kanopi adalah berbeza secara signifikan (P<0.05) antara aras kanopi dan antara perlakuan. Secara amnya, min bilangan telur dan larva B. tabaci adalah lebih tinggi secara bererti (P<0.05) pada aras kanopi atas berbanding tengah dan bawah. Walau bagaimanapun, min bilangan pupa B. tabaci adalah tinggi secara signifikan (P<0.05) pada aras kanopi bawah berbanding aras kanopi atas dan tengah. Min bilangan B. tabaci pada peringkat belum matang adalah berbeza secara bererti (P<0,05) mengikut minggu selepas pokok cili ditanam pada semua perlakuan. Secara amnya, populasi B. tabaci lebih tinggi semasa awal musim penanaman dan menurun selepasnya hingga ke akhir musim kecuali pada minggu ketiga dan ketujuh selepas pokok cili di tanam.

Matched MeSH terms: Vidarabine
Fulltext Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study

Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al.

J Clin Oncol, 2021 02 01;39(4):295-307.
PMID: 33332189 DOI: 10.1200/JCO.20.02529

PURPOSE: Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated whether preparative combination chemotherapy could replace TBI in such patients.
PATIENTS AND METHODS: FORUM is a randomized, controlled, open-label, international, multicenter, phase III, noninferiority study. Patients ≤ 18 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated donor were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority margin was 8%. With 1,000 patients randomly assigned in 5 years, 2-year minimum follow-up, and one-sided alpha of 5%, 80% power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129).
RESULTS: Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned, 212 received TBI, and 201 received chemoconditioning. The stopping rule was applied on March 31, 2019. The median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS) was significantly higher following TBI (0.91; 95% CI, 0.86 to 0.95; P < .0001) versus chemoconditioning (0.75; 95% CI, 0.67 to 0.81). Two-year cumulative incidence of relapse and treatment-related mortality were 0.12 (95% CI, 0.08 to 0.17; P < .0001) and 0.02 (95% CI, < 0.01 to 0.05; P = .0269) following TBI and 0.33 (95% CI, 0.25 to 0.40) and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respectively.
CONCLUSION: Improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemoconditioning. We therefore recommend TBI plus etoposide for patients > 4 years old with high-risk ALL undergoing allogeneic HSCT.

Matched MeSH terms: Vidarabine/administration & dosage; Vidarabine/analogs & derivatives
Fulltext Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience

Slatter MA, Rao K, Abd Hamid IJ, Nademi Z, Chiesa R, Elfeky R, et al.

Biol. Blood Marrow Transplant., 2018 03;24(3):529-536.
PMID: 29155317 DOI: 10.1016/j.bbmt.2017.11.009

We previously published results for 70 children who received conditioning with treosulfan and cyclophosphamide (n = 30) or fludarabine (n = 40) before undergoing hematopoietic stem cell transplantation (HSCT) for primary immunodeficiency (PID). Toxicity was lower and T cell chimerism was better in the patients receiving fludarabine, but cohort numbers were relatively small and follow-up was short. Here we report outcomes of 160 children who received homogeneous conditioning with treosulfan, fludarabine, and, in most cases, alemtuzumab (n = 124). The median age at transplantation was 1.36 years (range, .09 to 18.25 years). Donors included 73 matched unrelated, 54 1 to 3 antigen-mismatched unrelated, 12 matched sibling, 17 other matched family, and 4 haploidentical donors. Stem cell source was peripheral blood stem cells (PBSCs) in 70, bone marrow in 49, and cord blood in 41. Median duration of follow-up was 4.3 years (range, .8 to 9.4 years). Overall survival was 83%. No patients had veno-occlusive disease. Seventy-four patients (46%) had acute GVHD, but only 14 (9%) greater than grade II. Four patients underwent successful retransplantation for graft loss or poor immune reconstitution. Another patient experienced graft rejection and died. There was no association between T cell chimerism >95% and stem cell source, but a significant association was seen between myeloid chimerism >95% and use of PBSCs without an increased risk of significant GVHD compared with other sources. All 11 patients with severe combined immunodeficiency diagnosed at birth were alive at up to 8.7 years of follow-up. Long-term studies are needed to determine late gonadotoxic effects, and pharmacokinetic studies are needed to identify whether specific targeting is advantageous. The combination of treosulfan, fludarabine, and alemtuzumab is associated with excellent results in HSCT for PID.

Matched MeSH terms: Vidarabine/administration & dosage; Vidarabine/analogs & derivatives*
Fulltext Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenstrom Macroglobulinemia

Fadilah SA, Muhaya M, Azlin I

Med J Malaysia, 2007 Oct;62(4):349-51.
PMID: 18551947 MyJurnal

Irreversible optic nerve dysfunction associated with central retinal vein occlusion (CRVO) is an unusual but important complication of Waldenstrom Macroglobulinemia (WM). Acute visual loss in CRVO is mainly due the severe macular oedema. However, ischaemic optic neuropathy needs to be considered in patients with CRVO when, (i) there is a relative afferent papillary defect and central scotoma, (ii) the visual acuity is not consistent with the retinal pathology, and (iii) the visual defects persisted despite resolution of macular oedema following treatment of the hyperviscosity state. The ischaemic type of CRVO is associated with a poor visual prognosis and the presenting visual acuity has a prognostic role. We report the first description of irreversible unilateral optic nerve damage associated with CRVO in a patient with WM.

Matched MeSH terms: Vidarabine/administration & dosage; Vidarabine/analogs & derivatives
Fludarabine, High Dose Cytarabine and Granulocyte Colony-Stimulating Factor (FLAG) as Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia: A Retrospective Cohort Study

Law KB, Chang KM, Hamzah NA, Ng KH, Ong TC

Indian J Hematol Blood Transfus, 2017 Dec;33(4):483-491.
PMID: 29075058 DOI: 10.1007/s12288-017-0790-3

The study aimed to investigate the effect of consolidation treatment with fludarabine, high-dose cytarabine and granulocyte colony-stimulating factor or FLAG in older AML patients. The study included 41 eligible patients above 54 years old, who received both induction and consolidation chemotherapy for AML from 2008 to 2013. The study cohort had a minimum 24 months follow-up period. Survival analysis was carried out to assess patients' overall survival and disease free survival based on types of consolidation regimens. The consolidation treatment with FLAG exerted a protective effect to both overall survival and disease free survival in older patients. Patients who were consolidated with FLAG regimen had a significant longer overall survival (log-rank, p = 0.0025) and disease free survival (log-rank, p = 0.0026). The median overall survival was longer (18.70 months) with the use of FLAG when compared to non-FLAG group (8.09 months). The median disease free survival was also longer (13.84 months) with use of FLAG when compared to the non-FLAG group (4.44 months). Regression analysis with Cox model yielded hazard ratio of 0.245 (p = 0.0094) in overall survival and 0.217 (p = 0.0068) in disease free survival. The use of FLAG as consolidation treatment was associated with approximately 60-80% reduction in hazard rates. The result was adjusted for age, race and gender in regression analysis. Older AML patients had longer remission and survival when consolidated with FLAG regimen after the induction chemotherapy.

Matched MeSH terms: Vidarabine